The clinical evidence presented in this case suggested that cannabinoids administered concomitantly with other hepatotoxic substances may have augmented the risk and accelerated the progression of acute liver injury. However, further research is needed to definitively establish CBD oil as a contributing factor. While very few associations exist between cannabis oil and hepatotoxicity, our results suggest that cannabis oil is a critical co-factor for liver damage when used in conjunction with other drugs [5,6].

Several observations in the clinical course of the patient supported a synergistic hepatotoxicity hypothesis, where the concurrent utilization of cannabis oil, flucloxacillin, and paracetamol, each at a dose considered safe, resulted in severe hepatocellular injury, suggesting that the combination of these substances may have amplified the toxic effects rather than contributing independently to damage the liver. The biochemical pattern, with ALT levels greater than 6000IU/ml, indicated an amplification of the toxic effect rather than a simple additive injury. Additionally, the temporal relationship suggested that the liver abnormality occurred while the patient was using cannabis oil, in conjunction with the completion of a flucloxacillin course, indicating that the cannabinoids might prolong or exaggerate flucloxacillin's hepatotoxic potential. 

After a thorough literature search, we found that cannabinoids interact with different drugs, supporting Ben-Menachem et al., who found that cannabis and valproate increased stiripentol and ataxia-induced transaminitis in one patient [7]. Another study by Thai et al. gives some important pharmacokinetic evidence that cannabinoid (CBD) acts to inhibit CYP1A2 activity markedly, as was shown by 95% elevation in caffeine area under the curve (AUC) and prolonged elimination half-life when it's given concomitantly [8]. The hepatotoxic interactions observed in our case may be due to the potent inhibition of the key drug-metabolising enzyme, and many drugs actually known to be hepatotoxic (flucloxacillin, paracetamol, for example) require CYP1A2 clearance. Importantly, in the trial by Thai et al., six subjects had elevated liver transaminases, which adds support to CBD's propensity to cause liver injury by way of metabolic interference [8]. A systematic review and meta-analysis by Lo et al. demonstrated a significant association between CBD use and liver enzyme elevations and DILI, supporting the potential hepatotoxic effects of CBD [2].

These possible mechanisms are biologically plausible and may involve several pathways. Cannabinoids' ability to affect cytochrome P450 enzyme activity, in particular CYP3A4 and CYP2C9, which are highly important in the metabolism of flucloxacillin and paracetamol [9-11]. These metabolic interferences can result in increased levels of toxic drug metabolites, interference with normal detoxification pathways, and an increase in oxidative stress in hepatocytes. More recently, however, emerging research indicates that Δ9-THC and CBD may also directly intervene with hepatic mitochondrial function and promote apoptosis with attendant lowered threshold for DILI [12]. These mechanisms may have contributed to the liver dysfunction observed in our case study, despite the absence of classical risk factors, as CBD oil and its combination with other hepatotoxic materials possibly exacerbated the liver injury. However, the trends in bilirubin and albumin levels suggest that the hepatocellular failure was limited, despite the significant elevation of hepatic enzymes.

The administration of CBD-rich cannabis extract (CRCE) alongside acetaminophen to aged female CD-1 mice resulted in severe liver damage resembling sinusoidal obstruction syndrome, and it caused increased mortality rates together with enhanced activation of JNK signaling and oxidative stress pathways [13]. A report by Bass and Linz shows that CBD usage can cause unexpected liver damage alongside drug interaction effects [14]. The investigation conducted by Ewing et al. on male B6C3F1 mice demonstrated that acute and sub-acute CBD administrations caused hepatotoxic response by raising liver enzyme levels, increasing the weight of the liver, and generating substantial changes to stress-related genes and lipid regulatory genes [13]. Studies show that CBD leads to liver dysfunction effects primarily when patients consume the substance at elevated doses or maintain long-term usage [15,16].

Although cannabis is extensively used for medical benefits, it should not be ignored that these benefits do not negate serious potential adverse effects on both the liver and the nervous system functioning. The quick growth of cannabis product availability demands immediate regulatory control to establish standards for consistency, safety requirements, and usage guidelines [17]. Medical professionals must monitor patients who use cannabis products because these patients should be considered within the diagnosis process for unexplained liver harm and other potential toxic outcomes.

The medical evaluation of cannabis-induced liver damage faces difficulties because proper diagnostic standards are difficult to find. In the review by Eadie et al., medical staff concluded that DILI required exclusion methods to identify cannabis oil as the leading suspected origin of damage [18]. The clinical investigation and R Factor Scoring reveal the necessity of including cannabis oil diagnosis in excluding liver conditions that fail to have an identifiable etiology. This report highlights that while cannabis-induced hepatotoxicity remains rare, there is a possible correlation, underscoring the need for caution when prescribing pharmaceutical cannabis, particularly in persons with liver conditions or those with multiple diseases or multiple medications.